Drug news
Varisolve (BTG) success in VANISH-2 trial for Varicose Vein treatment
VANISH-2, the first of two US Phase III studies comparing Varisolve (polidocanol endovenous microfilm) from BTG with placebo in patients with symptomatic and visible Varicose Veins and saphenofemoral junction incompetence. The trial met all primary, secondary and tertiary efficacy endpoints.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins